Dual biological treatments in immune-mediated disorders: a single center experience
Dual biological treatment with omalizumab and another biologic appears to be safe, with no need to discontinue non-IgE-targeting agents during omalizumab therapy.
Authors
- Elchanan Parnasa
- Aviv Talmon
- Yuval Tal (ORCID: https://orcid.org/0000-0002-3633-2520)
- Limor Rubin (ORCID: https://orcid.org/0000-0001-5435-9420)
- Yaarit Ribak
- Hagit Peleg
- Oded Shamriz (ORCID: https://orcid.org/0000-0003-3188-2707)
- Ronit Confino‐Cohen
- Isaam Hindi
Institutions
- Tel Aviv University (IL)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
Publication Details
- Journal
- BMC Immunology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1186/s12865-025-00705-8
- Citations
- 1
- Primary Topic
- Urticaria and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 1.67